Advanced search
Publication Cover
Acta Cardiologica Volume 74, 2019 - Issue 1
Submit an article Journal homepage
225
Views
6
CrossRef citations to date
0
Altmetric
Original Scientific Paper

Dual antiplatelet therapy after percutaneous left atrial appendage occlusion: single center experience with the Amplatzer Cardiac Plug

Philippe B. BertrandHeart Center Hasselt, Jessa Ziekenhuis, Hasselt, Belgium; ;Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium
,
Melanie HabranFaculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium
,
Karlijn KenisFaculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium
,
Julie LecomteFaculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium
,
Linde MoonenFaculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium
,
Didier StroobantsHeart Center Hasselt, Jessa Ziekenhuis, Hasselt, Belgium;
&
Edouard BenitHeart Center Hasselt, Jessa Ziekenhuis, Hasselt, Belgium; Correspondence[email protected]
 show all
Pages 74-81 | Received 03 Jan 2018, Accepted 04 Mar 2018, Published online: 01 Apr 2018

References

  • Zoni-Berisso M, Lercari F, Carazza T, et al. Epidemiology of atrial fibrillation: European perspective. J Clin Epidemiol. 2014;6:e220.
  • Kirchhof P, Benussi S, Kotecha D, et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–2962.
  • Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–272.
  • Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57:173–180.
  • Casu G, Gulizia MM, Molon G, et al. ANMCO/AIAC/SICI-GISE/SIC/SICCH consensus document: percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation patients: indications, patient selection, staff skills, organisation, and training. Eur Heart J Suppl. 2017;19:D333–D353.
  • Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374:534–542.
  • Reddy VY, Doshi SK, Kar S, et al. 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol. 2017;70:2964–2975.
  • Holmes Jr DR, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64:1–12.
  • Tzikas A, Shakir S, Gafoor S, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention. 2016;11:1170–1179.
  • Plicht B, Konorza TF, Kahlert P, et al. Risk factors for thrombus formation on the Amplatzer Cardiac Plug after left atrial appendage occlusion. JACC Cardiovasc Interv.2013;6:606–613.
  • Park JW, Bethencourt A, Sievert H, et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. Cathet Cardiovasc Intervent. 2011;77:700–706.
  • Kefer J, Vermeersch P, Budts W, et al. Transcatheter left atrial appendage closure for stroke prevention in atrial fibrillation with Amplatzer cardiac plug: the Belgian Registry. Acta Cardiol. 2013;68:551–558.
  • Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736–2747.
  • Bertrand PB, Grieten L, De Meester P, et al. Etiology and relevance of the figure-of-eight artifact on echocardiography after percutaneous left atrial appendage closure with the Amplatzer Cardiac Plug. J Am Soc Echocardiogr. 2014;27:323–328 e1.
  • Bertrand PB, Grieten L, Smeets CJ, et al. The figure-of-eight artifact in the echocardiographic assessment of percutaneous disc occluders: impact of imaging depth and device type. Echocardiography. 2015;32:557–564.
  • Brandt RR, Neumann T, Neuzner J, et al. Transcatheter closure of atrial septal defect and patent foramen ovale in adult patients using the Amplatzer occlusion device: no evidence for thrombus deposition with antiplatelet agents. J Am Soc Echocardiogr. 2002;15:1094–1098.
  • Van de Bruaene A, Stroobants D, Benit E. Percutaneous closure of inter-atrial communications (atrial septal defect and patent foramen ovale): single-centre experience and mid-term follow-up. Acta Cardiol. 2015;70:133–140.
  • Lopez-Minguez JR, Eldoayen-Gragera J, Gonzalez-Fernandez R, et al. Immediate and one-year results in 35 consecutive patients after closure of left atrial appendage with the Amplatzer cardiac plug. Rev Esp Cardiol. 2013;66:90–97.
  • Lopez Minguez JR, Asensio JM, Gragera JE, et al. Two-year clinical outcome from the Iberian registry patients after left atrial appendage closure. Heart. 2015;101:877–883.
  • Freixa X, Abualsaud A, Chan J, et al. Left atrial appendage occlusion: initial experience with the Amplatzer Amulet. Int J Cardiol. 2014;174:492–496.
  • Reddy VY, Mobius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol. 2013;61:2551–2556.
  • Urena M, Rodes-Cabau J, Freixa X, et al. Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy. J Am Coll Cardiol. 2013;62:96–102.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Committed to improving the lives of patients with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.
Novartis. Your partner in Heart Failure & Atherosclerosis >>

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.